117 related articles for article (PubMed ID: 20509399)
1. Finding the magic formula for ESA use.
Neumann ME
Nephrol News Issues; 2010 May; 24(6):8. PubMed ID: 20509399
[No Abstract] [Full Text] [Related]
2. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
3. Has economics overshadowed our clinical approaches to EPO?
Sullivan JD
Nephrol News Issues; 2007 Jul; 21(8):56, 58-9, 68. PubMed ID: 17688233
[No Abstract] [Full Text] [Related]
4. A lesson from the EPO mess: stop the cost shifting.
Amerling R
Nephrol News Issues; 2007 Jul; 21(8):52, 54-5, 68. PubMed ID: 17688232
[No Abstract] [Full Text] [Related]
5. ESA payment changes: chasing a moving target.
Sargent JA
Nephrol News Issues; 2008 Jan; 22(1):36-7. PubMed ID: 18271437
[No Abstract] [Full Text] [Related]
6. Quality vs. quantity of life with ESAs: only patients should decide.
Schatell D
Nephrol News Issues; 2010 May; 24(6):14. PubMed ID: 20509400
[No Abstract] [Full Text] [Related]
7. Erythropoietin claims monitoring policy: implications for clinical practice.
Messana T
Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
[TBL] [Abstract][Full Text] [Related]
8. Anemia: dialysis patients experiences.
Schatell D; Witten B
Nephrol News Issues; 2004 Nov; 18(12):49-54. PubMed ID: 15595502
[No Abstract] [Full Text] [Related]
9. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure, part III.2: treatment of anaemia with iron.
Vaage-Nilsen O
Nephrol Dial Transplant; 2005 Jul; 20(7):1512-3; author reply 1513-4. PubMed ID: 15967789
[No Abstract] [Full Text] [Related]
10. Optimizing anemia management in hospitalized patients with end-stage renal disease.
Heung M; Mueller BA; Segal JH
Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
[TBL] [Abstract][Full Text] [Related]
11. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
12. FDA approval of Omontys changes the ESA playing field.
Neumann ME
Nephrol News Issues; 2012 May; 26(6):17. PubMed ID: 22690453
[No Abstract] [Full Text] [Related]
13. Peginesatide (Omontys) for anemia in chronic kidney failure.
Med Lett Drugs Ther; 2012 Jun; 54(1392):45-6. PubMed ID: 22683926
[No Abstract] [Full Text] [Related]
14. CERA: third-generation erythropoiesis-stimulating agent.
Topf JM
Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
[TBL] [Abstract][Full Text] [Related]
15. Anemia and cardiovascular risk in the patient with kidney disease.
Fishbane S
Heart Fail Clin; 2008 Oct; 4(4):401-10. PubMed ID: 18760752
[TBL] [Abstract][Full Text] [Related]
16. Current and future challenges in anaemia management.
Levin A; Locatelli F; Muirhead N; Ritz E
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi1-2. PubMed ID: 15958819
[No Abstract] [Full Text] [Related]
17. [Erythropoesis-stimulating agents: past, present and future].
Kes P; Basić-Jukić N
Acta Med Croatica; 2009 Sep; 63 Suppl 1():3-6. PubMed ID: 20235351
[TBL] [Abstract][Full Text] [Related]
18. Economic considerations in a changing anemia environment.
Pizzi LT
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
[TBL] [Abstract][Full Text] [Related]
19. Anaemia of CKD--the CHOIR study revisited.
Singh AK; Szczech L; Tang KL; Barnhart H; Sapp S; Wolfson M; Reddan D
Nephrol Dial Transplant; 2007 Jul; 22(7):1806-10. PubMed ID: 17420166
[No Abstract] [Full Text] [Related]
20. Creating a better environment to treat anemia in patients with CKD.
Sinnen MT
Nephrol Nurs J; 2007; 34(6):645-9. PubMed ID: 18203573
[No Abstract] [Full Text] [Related]
[Next] [New Search]
